CheckMan Stock Market Overview
Trending Stocks
Red List
In Today's Headlines
Planet Labs PBC (NYSE:PL) is set to report second-quarter earnings after the close tomorrow, Sept.
San Diego, California--(Newsfile Corp. - September 2, 2026) - Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 (the "Class Period"). The lawsuit alleges that Capricor Therapeutics misled investors regarding the path to FDA approval for its lead product candidate Deramiocel, a cell therapy to address cardiac and skeletal muscle complications associated with Duchenne muscular dystrophy.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bloom Energy To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Bloom Energy between February 27, 2025 and July 8, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - September 2, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bloom Energy Corporation ("Bloom Energy" or the "Company") (NYSE: BE) and reminds investors of the September 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Shares of the cybersecurity firm, which had a market value of around $5 billion, jumped on news of the discussions.
Thoma Bravo-owned Proofpoint is in talks to buy cybersecurity firm Varonis Systems , a source familiar with the matter told Reuters on Wednesday.
CUMMING, Ga., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Toll Brothers, Inc. (NYSE:TOL), the nation's leading builder of luxury homes, today announced the highly anticipated opening of its new model home at Toll Brothers at the Crossing at Coal Mountain in Cumming, Georgia.
Novartis' remibrutinib delivers positive phase III RMS results, reducing relapse rates versus Aubagio and supporting plans for global regulatory approvals.
Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.
HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.
HIMS has entered the second half of 2026 with weight-loss, international and AI momentum, but margin pressure and FDA uncertainty remain.